Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Algeta Initiates New Oncology Research Program to Conjugate Thorium-227 to Epratuzumab

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
CD22 is a well-validated target for hematological cancers.

Algeta ASA has initiated a new research program to evaluate a novel Targeted Thorium Conjugate (TTC) that combines Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with an anti-CD22 monoclonal antibody (epratuzumab) developed by Immunomedics, Inc..

Epratuzumab is a humanized monoclonal antibody (mAb) that binds to the CD22 glycoprotein on the surface of B cells. Epratuzumab has been evaluated for the treatment of a variety of hematological cancers and for autoimmune diseases such as systemic lupus erythematosus (SLE).

Under the terms of this agreement, Immunomedics will provide clinical-grade antibody to Algeta, which has rights to evaluate the potential of a TTC, linking thorium-227 to epratuzumab, for the treatment of cancer.

Algeta will fund all preclinical and clinical development costs up to the end of phase I testing. Upon successful completion of phase I testing, the parties shall negotiate terms for a license at Algeta’s request according to certain parameters now agreed between the companies.

Payments in the first year from Algeta to Immunomedics include a signature fee, an antibody delivery milestone and payments for cGMP antibody manufacture. No further details of the agreement are disclosed.

Thomas Ramdahl, Executive Vice President and Chief Technology Officer of Algeta, said: “The broad utility of our proprietary thorium-227 payload and its potential to be more effective at killing cancer cells than other therapeutic payloads gives Algeta a great opportunity to build an extensive pipeline of targeted cancer therapies. This collaboration brings together Algeta, the global leader in alpha-pharmaceuticals and Immunomedics, a pioneer in antibody products and technologies. A TTC based on a well-validated antibody such as epratuzumab is an exciting prospect as we work to achieve our goal of generating a clinical candidate from the TTC platform in 2014”.

Algeta’s TTC strategy is based on gaining access to carefully selected tumor-targeting molecules, via in-licensing, collaboration or via third parties, to which it links thorium-227 thereby creating potential new therapeutics.

Algeta’s disclosed TTC programs include collaborations with Sanofi and Ablynx, programs based on HER2-targeting (breast/ovarian cancer) and PDGFRβ-targeting (anti-angiogenesis) molecules in-licensed from Affibody and two programs targeting hematological cancers, including this newly announced program.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Algeta and Sanofi Extend Research Collaboration
Collaboration is focused on evaluating thorium-conjugated tumor-targeting antibody.
Monday, October 15, 2012
Algeta Signs License with Affibody for Tumor-Targeting Molecules
Algeta gains access to two proprietary Affibody® molecules for use in cancer therapy.
Tuesday, August 30, 2011
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos